Safety issues and prospects for future generations of PPAR modulators

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 8, 2007, Pages 1065-1081

  Rubenstrunk, Anne ^d   Hanf, Rémy ^d   Hum, Dean W ^d   Fruchart, Jean Charles ^a,b,c   Staels, Bart ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

^d Parc Eurasante Lille Metropole   (France)

Author keywords

Carcinogenesis; Congestive heart failure; Creatinine; Edema; Fluid retention; Homocysteine; Myopathy; PPAR agonists; Rhabdomyolysis; Safety issues; Side effects; SPPARM

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CREATININE; FARGLITAZAR; FENOFIBRATE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HOMOCYSTEINE; IMIGLITAZAR; INSULIN; METAGLIDASEN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; RAGAGLITAZAR; RIVOGLITAZONE; ROSIGLITAZONE; TESAGLITAZAR; TROGLITAZONE;

ANEMIA; ATHEROSCLEROSIS; CARCINOGENIC ACTIVITY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE BLOOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DYSLIPIDEMIA; EDEMA; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEMODILUTION; HOMOCYSTEINE BLOOD LEVEL; HUMAN; LEUKOPENIA; LIVER CANCER; LIVER FUNCTION TEST; LIVER TOXICITY; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STONE FORMATION; WEIGHT GAIN;

ANTILIPEMIC AGENTS; CLINICAL TRIALS; DIABETES MELLITUS; HEART; HUMANS; HYPOGLYCEMIC AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SAFETY;

RODENTIA;

EID: 34547661569     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.02.003     Document Type: Review

References (201)

1. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., and Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355 (2006) 2427-2443
2. Nathan D.M. Thiazolidinediones for initial treatment of type 2 diabetes?. N. Engl. J. Med. 355 (2006) 2477-2480
3. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
4. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino Sr. R.B., Perez A., Provost J.C., and Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006)
5. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
6. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., Hanefeld M., Hoogwerf B., Laakso M., Mohan V., Shaw J., Zinman B., and Holman R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
7. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., and Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
8. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317 (1987) 1237-1245
9. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
10. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341 (1999) 410-418
11. Albert C. A randomized trial of folic acid and B-vitamins in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS). Late Breaking Trials I (2006), American Heart Association 2006 Scientific Sessions (November 13th)
12. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 2 (1980) 379-385
13. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
14. Chinetti G., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49 (2000) 497-505
15. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 (2005) 244-251
16. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18 (2002) 269-276
17. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., and Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 717-726
18. Jiang G., Dallas-Yang Q., Li Z., Szalkowski D., Liu F., Shen X., Wu M., Zhou G., Doebber T., Berger J., Moller D.E., and Zhang B.B. Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists. Diabetes 51 (2002) 2412-2419
19. Picard F., and Auwerx J. PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 22 (2002) 167-197
20. Walter H., and Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs 65 (2005) 1-13
21. Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., Mari A., and Defronzo R.A. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am. J. Physiol., Endocrinol. Metab. (2006)
22. Barish G.D., Narkar V.A., and Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116 (2006) 590-597
23. Luquet S., Gaudel C., Holst D., Lopez-Soriano J., Jehl-Pietri C., Fredenrich A., and Grimaldi P.A. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta 1740 (2005) 313-317
24. Gross B.S., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptor b/d: a novel target for the reduction of atherosclerosis. Drug Discov. Today Ther. Strat. 2 (2005)
25. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
26. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., Dubuquoy L., Bac P., Champy M.F., Plunket K.D., Leesnitzer L.M., Blanchard S.G., Desreumaux P., Moras D., Renaud J.P., and Auwerx J. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8 (2001) 737-747
27. Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., Elbrecht A., Johnson B.A., Zhou G., Doebber T.W., Biswas C., Parikh M., Sharma N., Tanen M.R., Thompson G.M., Ventre J., Adams A.D., Mosley R., Surwit R.S., and Moller D.E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 17 (2003) 662-676
28. Liu K., Black R.M., Acton J.J., Mosley R., Debenham S., Abola R., Yang M., Tschirret-Guth R., Colwell L., Liu C., Wu M., Wang C.F., MacNaul K.L., McCann M.E., Moller D.E., Berger J.P., Meinke P.T., Jones A.B., and Wood H.B. Selective PPARgamma modulators with improved pharmacological profiles. Bioorg. Med. Chem. Lett. 15 (2005) 2437-2440
29. Fujimura T., Sakuma H., Konishi S., Oe T., Hosogai N., Kimura C., Aramori I., and Mutoh S. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J. Pharmacol. Sci. 99 (2005) 342-352
30. Xu Y., Etgen G.J., Broderick C.L., Canada E., Gonzalez I., Lamar J., Montrose-Rafizadeh C., Oldham B.A., Osborne J.J., Xie C., Shi Q., Winneroski L.L., York J., Yumibe N., Zink R., and Mantlo N. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile. J. Med. Chem. 49 (2006) 5649-5652
31. Watkins P.B., and Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338 (1998) 916-917
32. Lebovitz H.E., Kreider M., and Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 25 (2002) 815-821
33. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 (2004) 256-263
34. Werner A.L., and Travaglini M.T. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21 (2001) 1082-1099
35. Hollenberg N.K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am. J. Med. 115 Suppl 8A (2003) 111S-115S
36. Fagerberg B., Edwards S., Halmos T., Lopatynski J., Schuster H., Stender S., Stoa-Birketvedt G., Tonstad S., Halldorsdottir S., and Gause-Nilsson I. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716-1725
37. Henry R.R. Thiazolidinediones. Endocrinol. Metab. Clin. North Am. 26 (1997) 553-573
38. Zhang H., Zhang A., Kohan D.E., Nelson R.D., Gonzalez F.J., and Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9406-9411
39. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., and Breyer M.D. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11 (2005) 861-866
40. Chen L., Yang B., McNulty J.A., Clifton L.G., Binz J.G., Grimes A.M., Strum J.C., Harrington W.W., Chen Z., Balon T.W., Stimpson S.A., and Brown K.K. GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats. J. Pharmacol. Exp. Ther. 312 (2005) 718-725
41. Yang B., Clifton L.G., McNulty J.A., Chen L., Brown K.K., and Baer P.G. Effects of a PPARgamma agonist, GI262570, on renal filtration fraction and nitric oxide level in conscious rats. J. Cardiovasc. Pharmacol. 42 (2003) 436-441
42. Zanchi A., Chiolero A., Maillard M., Nussberger J., Brunner H.R., and Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J. Clin. Endocrinol. Metab. 89 (2004) 1140-1145
43. Hong G., Lockhart A., Davis B., Rahmoune H., Baker S., Ye L., Thompson P., Shou Y., O'Shaughnessy K., Ronco P., and Brown J. PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J. 17 (2003) 1966-1968
44. Fonseca V.A., Valiquett T.R., Huang S.M., Ghazzi M.N., and Whitcomb R.W. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J. Clin. Endocrinol. Metab. 83 (1998) 3169-3176
45. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86 (2001) 280-288
46. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000) 1605-1611
47. Rosenstock J., Einhorn D., Hershon K., Glazer N.B., and Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int. J. Clin. Pract. 56 (2002) 251-257
48. Buse J.B., Gumbiner B., Mathias N.P., Nelson D.M., Faja B.W., and Whitcomb R.W. Troglitazone use in insulin-treated type 2 diabetic patients. The troglitazone insulin study group. Diabetes Care 21 (1998) 1455-1461
49. Mudaliar S., Chang A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr. Pract. 9 (2003) 406-416
50. Page II R.L., Gozansky W.S., and Ruscin J.M. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 23 (2003) 945-954
51. Zhang F., Sowers J.R., Ram J.L., Standley P.R., and Peuler J.D. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24 (1994) 170-175
52. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., Scott S., Rude R.K., and Hsueh W.A. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J. Clin. Invest. 96 (1995) 354-360
53. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94 (2004) 1168-1178
54. Yamakawa K., Hosoi M., Koyama H., Tanaka S., Fukumoto S., Morii H., and Nishizawa Y. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 271 (2000) 571-574
55. Baba T., Shimada K., Neugebauer S., Yamada D., Hashimoto S., and Watanabe T. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 24 (2001) 953-954
56. Inoue M., Itoh H., Tanaka T., Chun T.H., Doi K., Fukunaga Y., Sawada N., Yamshita J., Masatsugu K., Saito T., Sakaguchi S., Sone M., Yamahara K., Yurugi T., and Nakao K. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 560-566
57. Chelliah A., and Burge M.R. Insulin edema in the twenty-first century: review of the existing literature. J. Investig. Med. 52 (2004) 104-108
58. Walker A.B., Naderali E.K., Chattington P.D., Buckingham R.E., and Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 47 (1998) 810-814
59. Idris I., Gray S., and Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 46 (2003) 288-290
60. Rennings A.J., Smits P., Stewart M.W., and Tack C.J. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 29 (2006) 581-587
61. Hinder F., Booke M., Traber L.D., and Traber D.L. Nitric oxide and endothelial permeability. J. Appl. Physiol. 83 (1997) 1941-1946
62. Patel C., Wyne K.L., and McGuire D.K. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?. Diab. Vasc. Dis. Res. 2 (2005) 61-66
63. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., and Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46 (1997) 433-439
64. St John Sutton M., Rendell M., Dandona P., Dole J.F., Murphy K., Patwardhan R., Patel J., and Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25 (2002) 2058-2064
65. Tang W.H., Francis G.S., Hoogwerf B.J., and Young J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J. Am. Coll. Cardiol. 41 (2003) 1394-1398
66. Rajagopalan R., Rosenson R.S., Fernandes A.W., Khan M., and Murray F.T. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin. Ther. 26 (2004) 1400-1410
67. Shimoyama M., Ogino K., Tanaka Y., Ikeda T., and Hisatome I. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 48 (1999) 609-615
68. Shimabukuro M., Higa S., Shinzato T., Nagamine F., Komiya I., and Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 45 (1996) 1168-1173
69. Yao L., Mizushige K., Noma T., Murakami K., Ohmori K., and Matsuo H. Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment. Angiology 52 (2001) 53-57
70. Asakawa M., Takano H., Nagai T., Uozumi H., Hasegawa H., Kubota N., Saito T., Masuda Y., Kadowaki T., and Komuro I. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105 (2002) 1240-1246
71. Yamamoto K., Ohki R., Lee R.T., Ikeda U., and Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104 (2001) 1670-1675
72. Tsuji T., Mizushige K., Noma T., Murakami K., Ohmori K., Miyatake A., and Kohno M. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J. Cardiovasc. Pharmacol. 38 (2001) 868-874
73. Yue T.L., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., and Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104 (2001) 2588-2594
74. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., Ishibashi M., Kubota T., Egashira K., and Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
75. Chilcott J., Tappenden P., Jones M.L., and Wight J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin. Ther. 23 (2001) 1792-1823 (discussion 1791)
76. Khan M.A., St Peter J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25 (2002) 708-711
77. Kelly I.E., Han T.S., Walsh K., and Lean M.E. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22 (1999) 288-293
78. Nakamura T., Funahashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., Hotta K., Kuriyama H., Kihara S., Ohuchi N., Nishimura T., Kishino B.I., Ishikawa K., Kawamoto T., Tokunaga K., Nakagawa C., Mineo I., Watanabe F., Tarui S., and Matsuzawa Y. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res. Clin. Pract. 54 (2001) 181-190
79. Akazawa S., Sun F., Ito M., Kawasaki E., and Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23 (2000) 1067-1071
80. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., Mandarino L.J., and DeFronzo R.A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87 (2002) 2784-2791
81. Shimizu H., Tsuchiya T., Sato N., Shimomura Y., Kobayashi I., and Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 21 (1998) 1470-1474
82. Rumi M.A., Ishihara S., Kazumori H., Kadowaki Y., and Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy?. Curr. Med. Chem. Anticancer Agents 4 (2004) 465-477
83. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., Banayo E., Cardiff R.D., Izpisua-Belmonte J.C., and Evans R.M. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 18 (2004) 528-540
84. Lefebvre A.M., Chen I., Desreumaux P., Najib J., Fruchart J.C., Geboes K., Briggs M., Heyman R., and Auwerx J. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 4 (1998) 1053-1057
85. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., Thomazy V.A., and Evans R.M. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 4 (1998) 1058-1061
86. Pino M.V., Kelley M.F., and Jayyosi Z. Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist. Toxicol. Pathol. 32 (2004) 58-63
87. Yang K., Fan K.H., Lamprecht S.A., Edelmann W., Kopelovich L., Kucherlapati R., and Lipkin M. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int. J. Cancer 116 (2005) 495-499
88. Kopp H.G., Ramos C.A., and Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13 (2006) 175-181
89. De Palma M., and Naldini L. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim. Biophys. Acta 1766 (2006) 159-166
90. Gensch C., Clever Y.P., Werner C., Hanhoun M., Bohm M., and Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis (2006)
91. Egerod F.L., Nielsen H.S., Iversen L., Thorup I., Storgaard T., and Oleksiewicz M.B. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 10 (2005) 295-309
92. Oleksiewicz M.B., Thorup I., Nielsen H.S., Andersen H.V., Hegelund A.C., Iversen L., Guldberg T.S., Brinck P.R., Sjogren I., Thinggaard U.K., Jorgensen L., and Jensen M.B. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol. Pathol. 33 (2005) 552-560
93. Cohen S.M. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol. Sci. 87 (2005) 322-327
94. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., and Juarbe H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129 (1998) 36-38
95. Herrine S.K., and Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann. Intern. Med. 130 (1999) 163-164
96. Neuschwander-Tetri B.A., Isley W.L., Oki J.C., Ramrakhiani S., Quiason S.G., Phillips N.J., and Brunt E.M. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Intern. Med. 129 (1998) 38-41
97. Asami-Miyagishi R., Iseki S., Usui M., Uchida K., Kubo H., and Morita I. Expression and function of PPARgamma in rat placental development. Biochem. Biophys. Res. Commun. 315 (2004) 497-501
98. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585-595
99. Kalyoncu N.I., Yaris F., Ulku C., Kadioglu M., Kesim M., Unsal M., Dikici M., and Yaris E. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod. Toxicol. 19 (2005) 563-564
100. Yaris F., Yaris E., Kadioglu M., Ulku C., Kesim M., and Kalyoncu N.I. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod. Toxicol. 18 (2004) 619-621
101. Zimetbaum P., Frishman W.H., and Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J. Clin. Pharmacol. 31 (1991) 25-37
102. Layne R.D., Sehbai A.S., and Stark L.J. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann. Pharmacother. 38 (2004) 232-234
103. Magarian G.J., Lucas L.M., and Colley C. Gemfibrozil-induced myopathy. Arch. Intern. Med. 151 (1991) 1873-1874
104. Gorriz J.L., Sancho A., Lopez-Martin J.M., Alcoy E., Catalan C., and Pallardo L.M. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 74 (1996) 437-438
105. Blane G.F., and Pinaroli F. [Fenofibrate: animal toxicology in relation to side-effects in man (author's translation)]. Nouv. Presse Med. 9 (1980) 3737-3746
106. Clouatre Y., Leblanc M., Ouimet D., and Pichette V. Fenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidism. Nephrol. Dial. Transplant. 14 (1999) 1047-1048
107. Barker B.J., Goodenough R.R., and Falko J.M. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 26 (2003) 2482-2483
108. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am. J. Cardiol. 94 (2004) 935-938
109. Langer T., and Levy R.I. Acute muscular syndrome associated with administration of clofibrate. N. Engl. J. Med. 279 (1968) 856-858
110. Bridgman J.F., Rosen S.M., and Thorp J.M. Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. Lancet 2 (1972) 506-509
111. Rush P., Baron M., and Kapusta M. Clofibrate myopathy: a case report and a review of the literature. Semin. Arthritis Rheum. 15 (1986) 226-229
112. Rumpf K.W., Barth M., Blech M., Kaiser H., Koop I., Arnold R., and Scheler F. Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function. Klin. Wochenschr. 62 (1984) 346-348
113. Gorriz J.L., Sancho A., Alcoy E., Garcia-Ramos J.L., and Pallardo L.M. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol. Dial. Transplant. 10 (1995) 2371-2372
114. Heidemann H., and Bock K.D. Rhabdomyolysis with acute renal failure due to bezafibrate. Klin. Wochenschr. 59 (1981) 413-414
115. Graham D.J., Staffa J.A., Shatin D., Andrade S.E., Schech S.D., La Grenade L., Gurwitz J.H., Chan K.A., Goodman M.J., and Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 (2004) 2585-2590
116. Pierce L.R., Wysowski D.K., and Gross T.P. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 264 (1990) 71-75
117. Levak-Frank S., Radner H., Walsh A., Stollberger R., Knipping G., Hoefler G., Sattler W., Weinstock P.H., Breslow J.L., and Zechner R. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J. Clin. Invest. 96 (1995) 976-986
118. Motojima K. A metabolic switching hypothesis for the first step in the hypolipidemic effects of fibrates. Biol. Pharm. Bull. 25 (2002) 1509-1511
119. Motojima K., and Seto K. Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice. Biol. Pharm. Bull. 26 (2003) 954-958
120. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128 (2002) 159-168
121. Gaist D., Rodriguez L.A., Huerta C., Hallas J., and Sindrup S.H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12 (2001) 565-569
122. Bermingham R.P., Whitsitt T.B., Smart M.L., Nowak D.P., and Scalley R.D. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am. J. Health Syst. Pharm. 57 (2000) 461-464
123. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95 (2005) 120-122
124. Jacobson T.A., and Zimmerman F.H. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. (Greenwich, Conn.) 8 (2006) 35-41 (quiz 42-3)
125. Broeders N., Knoop C., Antoine M., Tielemans C., and Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol. Dial. Transplant. 15 (2000) 1993-1999
126. Decaudin B., Beraud G., Lannoy D., Semjen E., Wierre L., Horrent S., Resibois J.P., Azar R., and Odou P. Fibrate-induced increase in serum creatinine levels: two cases. Therapie 60 (2005) 601-602
127. Ritter J.L., and Nabulsi S. Fenofibrate-Induced elevation in serum creatinine. Pharmacotherapy 21 (2001) 1145-1149
128. Lipkin G.W., and Tomson C.R. Severe reversible renal failure with bezafibrate. Lancet 341 (1993) 371
129. Tsimihodimos V., Kakafika A., and Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol. Dial. Transplant. 16 (2001) 1301
130. Lipscombe J., and Bargman J.M. Fibrate-induced increase in blood urea and creatinine. Nephrol. Dial. Transplant. 16 (2001) 1515
131. Tonelli M., Collins D., Robins S., Bloomfield H., and Curhan G.C. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am. J. Kidney Dis. 44 (2004) 832-839
132. Ledwith B.J., Pauley C.J., Wagner L.K., Rokos C.L., Alberts D.W., and Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J. Biol. Chem. 272 (1997) 3707-3714
133. Devuyst O., Goffin E., Pirson Y., and van Ypersele de Strihou C. Creatinine rise after fibrate therapy in renal graft recipients. Lancet 341 (1993) 840
134. Yoshinari M., Asano T., Kaori S., Shi A.H., Wakisaka M., Iwase M., and Fujishima M. Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 42 (1998) 149-154
135. Lipscombe J., Lewis G.F., Cattran D., and Bargman J.M. Deterioration in renal function associated with fibrate therapy. Clin. Nephrol. 55 (2001) 39-44
136. Tsimihodimos V., Miltiadous G., Bairaktari E., and Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin. Nephrol. 57 (2002) 407-408
137. Hottelart C., el Esper N., Achard J.M., Pruna A., and Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 20 (1999) 41-44
138. Hottelart C., El Esper N., Rose F., Achard J.M., and Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92 (2002) 536-541
139. Brown W.V. Potential use of fenofibrate and other fibric acid derivatives in the clinic. Am. J. Med. 83 (1987) 85-89
140. Blane G.F. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am. J. Med. 83 (1987) 26-36
141. Dierkes J., Westphal S., and Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354 (1999) 219-220
142. Westphal S., Dierkes J., and Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358 (2001) 39-40
143. de Lorgeril M., Salen P., Paillard F., Lacan P., and Richard G. Lipid-lowering drugs and homocysteine. Lancet 353 (1999) 209-210
144. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., and Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154 (2001) 421-427
145. Harats D., Yodfat O., Doolman R., Gavendo S., Marko D., Shaish A., and Sela B.A. Homocysteine elevation with fibrates: is it a class effect?. Isr. Med. Assoc. J. 3 (2001) 243-246
146. Schaefer E., Macnamara J., Selhub J., Bostom A., Collins D., Rubins H., and Robins S. Gemfibrozil treatment raised homocysteine concentrations in VA-HIT. Circulation 102 (2000) II847
147. Dierkes J., Westphal S., and Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin. Drug Saf. 3 (2004) 101-111
148. Brattstrom L.E., Israelsson B., Jeppsson J.O., and Hultberg B.L. Folic acid-an innocuous means to reduce plasma homocysteine. Scand. J. Clin. Lab. Invest. 48 (1988) 215-221
149. Ubbink J.B., Vermaak W.J., van der Merwe A., Becker P.J., Delport R., and Potgieter H.C. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J. Nutr. 124 (1994) 1927-1933
150. Brattstrom L., Israelsson B., Norrving B., Bergqvist D., Thorne J., Hultberg B., and Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 81 (1990) 51-60
151. Brattstrom L.E., Hultberg B.L., and Hardebo J.E. Folic acid responsive postmenopausal homocysteinemia. Metabolism 34 (1985) 1073-1077
152. Franken D.G., Boers G.H., Blom H.J., Trijbels F.J., and Kloppenborg P.W. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler. Thromb. 14 (1994) 465-470
153. Ubbink J.B., Vermaak W.J., van der Merwe A., and Becker P.J. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am. J. Clin. Nutr. 57 (1993) 47-53
154. Ubbink J.B., van der Merwe A., Vermaak W.J., and Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin. Investig. 71 (1993) 993-998
155. Dierkes J., Westphal S., Kunstmann S., Banditt P., Lossner A., and Luley C. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 158 (2001) 161-164
156. Melenovsky V., Stulc T., Kozich V., Grauova B., Krijt J., Wichterle D., Haas T., Malik J., Hradec J., and Ceska R. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. Am. Heart J. 146 (2003) 110
157. Stulc T., Melenovsky V., Grauova B., Kozich V., and Ceska R. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. Nutrition 17 (2001) 721-723
158. Mayer Jr. O., Simon J., Holubec L., Pikner R., and Subrt I. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. Eur. J. Clin. Pharmacol. 59 (2003) 367-371
159. Luc G., Jacob N., Bouly M., Fruchart J.C., Staels B., and Giral P. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J. Cardiovasc. Pharmacol. 43 (2004) 452-453
160. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
161. den Heijer M., and Keijzer M.B. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin. Chem. Lab. Med. 39 (2001) 710-713
162. Eikelboom J.W., Lonn E., Genest Jr. J., Hankey G., and Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131 (1999) 363-375
163. Liao D., Tan H., Hui R., Li Z., Jiang X., Gaubatz J., Yang F., Durante W., Chan L., Schafer A.I., Pownall H.J., Yang X., and Wang H. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ. Res. 99 (2006) 598-606
164. Mikael L.G., Genest Jr. J., and Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 98 (2006) 564-571
165. Chen C., Surowiec S.M., Morsy A.H., and Ma M. Intraperitoneal infusion of homocysteine increases intimal hyperplasia in balloon-injured rat carotid arteries. Atherosclerosis 160 (2002) 103-114
166. Southern F.N., Cruz N., Fink L.M., Cooney C.A., Barone G.W., Eidt J.F., and Moursi M.M. Hyperhomocysteinemia increases intimal hyperplasia in a rat carotid endarterectomy model. J. Vasc. Surg. 28 (1998) 909-918
167. Southern F., Eidt J., Drouilhet J., Mukunyadzi P., Williams D.K., Cruz C., Wang Y.F., Poirier L.A., Brown A.T., and Moursi M.M. Increasing levels of dietary homocystine with carotid endarterectomy produced proportionate increases in plasma homocysteine and intimal hyperplasia. Atherosclerosis 158 (2001) 129-138
168. Aizawa Y., Kawabe J., Hasebe N., Takehara N., and Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 104 (2001) 455-460
169. Desouza C.V., Murthy S.N., Diez J., Dunne B., Matta A.S., Fonseca V.A., and McNamara D.B. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J. Cardiovasc. Pharmacol. Ther. 8 (2003) 297-305
170. Murthy S.N., Obregon D.F., Chattergoon N.N., Fonseca N.A., Mondal D., Dunne J.B., Diez J.G., Jeter Jr. J.R., Kadowitz P.J., Agrawal K.C., McNamara D.B., and Fonseca V.A. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism 54 (2005) 645-652
171. Bateson M.C., Maclean D., Ross P.E., and Bouchier I.A. Clofibrate therapy and gallstone induction. Am. J. Dig. Dis. 23 (1978) 623-628
172. Caroli-Bosc F.X., Le Gall P., Pugliese P., Delabre B., Caroli-Bosc C., Demarquay J.F., Delmont J.P., Rampal P., and Montet J.C. Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. Dig. Dis. Sci. 46 (2001) 540-544
173. Mazzella G., Bazzoli F., Villanova N., Simoni P., Festi D., Roda A., Aldini R., and Roda E. Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate. Scand. J. Gastroenterol. 25 (1990) 1227-1234
174. Post S.M., Duez H., Gervois P.P., Staels B., Kuipers F., and Princen H.M. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1840-1845
175. Hays T., Rusyn I., Burns A.M., Kennett M.J., Ward J.M., Gonzalez F.J., and Peters J.M. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26 (2005) 219-227
176. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., Han X., Gross R.W., Kozak R., Lopaschuk G.D., and Kelly D.P. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109 (2002) 121-130
177. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., Gross R.W., and Kelly D.P. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1226-1231
178. Park S.Y., Cho Y.R., Finck B.N., Kim H.J., Higashimori T., Hong E.G., Lee M.K., Danton C., Deshmukh S., Cline G.W., Wu J.J., Bennett A.M., Rothermel B., Kalinowski A., Russell K.S., Kim Y.B., Kelly D.P., and Kim J.K. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes 54 (2005) 2514-2524
179. Cook W.S., Yeldandi A.V., Rao M.S., Hashimoto T., and Reddy J.K. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha. Biochem. Biophys. Res. Commun. 278 (2000) 250-257
180. Pruimboom-Brees I., Haghpassand M., Royer L., Brees D., Aldinger C., Reagan W., Singh J., Kerlin R., Kane C., Bagley S., Hayward C., Loy J., O'Brien P., and Francone O.L. A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. Am. J. Pathol. 169 (2006) 750-760
181. Aasum E., Belke D.D., Severson D.L., Riemersma R.A., Cooper M., Andreassen M., and Larsen T.S. Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am. J. Physiol., Heart Circ. Physiol. 283 (2002) H949-H957
182. Bulhak A.A., Sjoquist P.O., Xu C.B., Edvinsson L., and Pernow J. Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res. Cardiol. 101 (2006) 244-252
183. Yue T.L., Bao W., Jucker B.M., Gu J.L., Romanic A.M., Brown P.J., Cui J., Thudium D.T., Boyce R., Burns-Kurtis C.L., Mirabile R.C., Aravindhan K., and Ohlstein E.H. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation 108 (2003) 2393-2399
184. Reddy J.K., and Chu R. Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon. Ann. N. Y. Acad. Sci. 804 (1996) 176-201
185. Peters J.M., Cattley R.C., and Gonzalez F.J. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18 (1997) 2029-2033
186. Lee S.S., Pineau T., Drago J., Lee E.J., Owens J.W., Kroetz D.L., Fernandez-Salguero P.M., Westphal H., and Gonzalez F.J. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 (1995) 3012-3022
187. Balfour J.A., McTavish D., and Heel R.C. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 40 (1990) 260-290
188. Klaunig J.E., Babich M.A., Baetcke K.P., Cook J.C., Corton J.C., David R.M., DeLuca J.G., Lai D.Y., McKee R.H., Peters J.M., Roberts R.A., and Fenner-Crisp P.A. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33 (2003) 655-780
189. Cibelli A., Stefanini S., and Ceru M.P. Peroxisomal beta-oxidation and catalase activities in fetal rat liver: effect of maternal treatment with clofibrate. Cell. Mol. Biol. 34 (1988) 191-205
190. Wilson G.N., King T., Argyle J.C., and Garcia R.F. Maternal clofibrate administration amplifies fetal peroxisomes. Pediatr. Res. 29 (1991) 256-262
191. Stefanini S., Mauriello A., Farrace M.G., Cibelli A., and Ceru M.P. Proliferative response of foetal liver peroxisomes to clofibrate treatment of pregnant rats. A quantitative evaluation. Biol. Cell 67 (1989) 299-305
192. Fitzgerald J.E., Petrere J.A., and de la Iglesia F.A. Experimental studies on reproduction with the lipid-regulating agent gemfibrozil. Fundam. Appl. Toxicol. 8 (1987) 454-464
193. Pantaleoni G.C., and Valeri P. Studies of the interactions of clofibrate with the reproductive function. Clin. Ter. 69 (1974) 321-328
194. Gupta R.A., Wang D., Katkuri S., Wang H., Dey S.K., and DuBois R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med. 10 (2004) 245-247
195. Marin H.E., Peraza M.A., Billin A.N., Willson T.M., Ward J.M., Kennett M.J., Gonzalez F.J., and Peters J.M. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 66 (2006) 4394-4401
196. Harman F.S., Nicol C.J., Marin H.E., Ward J.M., Gonzalez F.J., and Peters J.M. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat. Med. 10 (2004) 481-483
197. Reed K.R., Sansom O.J., Hayes A.J., Gescher A.J., Winton D.J., Peters J.M., and Clarke A.R. PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23 (2004) 8992-8996
198. Fievet C., Fruchart J.C., and Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 6 (2006) 606-614
199. E.M. Wulff, L. Jeppesen, P.S. Bury, J.P. Mogensen, J. Fleckner, A.T. Andersen, K. Wassermann, P. Sauerberg, The anti-diabetic activity of the dual acting PPARa/g agonist ragaglitazar: a comparative study with known insulin sensitizers in vitro and in vivo, EASD Abstract-Poster Session #53 (2002).
200. Sakamoto J., Kimura H., Moriyama S., Imoto H., Momose Y., Odaka H., and Sawada H. A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur. J. Pharmacol. 495 (2004) 17-26
201. Shek A., and Ferrill M.J. Statin-fibrate combination therapy. Ann. Pharmacother. 35 (2001) 908-917